<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1125">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146505</url>
  </required_header>
  <id_info>
    <org_study_id>788/2021/Sper/AOUBo</org_study_id>
    <nct_id>NCT05146505</nct_id>
  </id_info>
  <brief_title>miRNAs in High Grade Serous Ovarian Cancer</brief_title>
  <acronym>MIROC</acronym>
  <official_title>Analysis of Circulating miRNAs as Potential Biomarkers of Diagnosis and Prognosis in High Grade Serous Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High grade serous ovarian cancer represents the gynecological malignancy with the highest&#xD;
      incidence of mortality. Decision-making tools are currently limited to the use of standard&#xD;
      imaging modalities and analysis of serum biomarkers, such as CA 125, which often have low&#xD;
      specificity and sensitivity. Recently, a growing research interest has been aimed at&#xD;
      so-called circulating microRNAs (miRNAs). Indeed, it has been observed that miRNAs are&#xD;
      abundantly present in all biological fluids and play the key role of messengers in&#xD;
      intercellular communication. Cancer cells have a rapid turnover which results in a continuous&#xD;
      release of nucleic acids and vesicles derived from the tumor itself, such as the tumor cells&#xD;
      themselves that separate from the tumor mass to enter the bloodstream. Given their important&#xD;
      role as modulators of gene expression, in order to preserve their integrity, miRNAs are&#xD;
      encapsulated in specific vesicles, in order to prevent their degradation by the enzymes&#xD;
      present in biological fluids. In this context, the chance of monitoring the expression levels&#xD;
      of specific miRNAs represents a very interesting option both for an early diagnosis and for&#xD;
      monitoring the clinical response to pharmacological treatment. Currently, there are no&#xD;
      non-invasive approaches to monitor the clinical outcome in real time, while the&#xD;
      identification of circulating biomarkers would allow prompt intervention, possibly modifying&#xD;
      the pharmacological management in case of progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal miRNAs analysis over chemotherapy</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of miRNA expression in longitudinal blood samples collected during every follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associaition miRNA-clinico-pathological data</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation between miRNAs deregulation and clinico-pathological and molecular data</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>High Grade Serous Ovarian Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with high grade serous ovarian cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt;18&#xD;
&#xD;
          -  Histological diagnosis of epithelial ovarian cancer&#xD;
&#xD;
          -  Patients eligible for surgery&#xD;
&#xD;
          -  Patients followed in the clinical care pathway c / o oncological gynecology (surgery&#xD;
             and follow up)&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with HCV, HBV and HIV&#xD;
&#xD;
          -  Patients with other malignancies diagnosed less than 5 years prior to the diagnosis of&#xD;
             ovarian malignancy&#xD;
&#xD;
          -  Ovarian metastases of primary neoplasms of other organs&#xD;
&#xD;
          -  Presence of ascites for non-neoplastic causes&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Myriam Perrone</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS- Azienda Ospedaliera-Universitaria di Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Myriam Perrone, MD</last_name>
    <phone>+39 051 2144392</phone>
    <email>myriam.perrone@aosp.bo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Myriam Perrone</last_name>
    <phone>+39 051 2144392</phone>
    <email>myriam.perrone@aosp.bo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS- Azienda Ospedaliera-Universitaria di Bologna</name>
      <address>
        <city>Bologna</city>
        <state>Bo</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Myriam Perrone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anna Myriam Perrone</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierandrea De IAco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 20, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Anna Myriam Perrone</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>miRNAs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

